Shield Therapeutics Gelecekteki Büyüme
Future kriter kontrolleri 5/6
Shield Therapeutics kazanç ve gelirin sırasıyla yıllık 109.8% ve 24.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 111.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -4.7% olacağı tahmin edilmektedir.
Anahtar bilgiler
109.8%
Kazanç büyüme oranı
111.93%
EPS büyüme oranı
| Pharmaceuticals kazanç büyümesi | 10.4% |
| Gelir büyüme oranı | 24.1% |
| Gelecekteki özkaynak getirisi | -4.70% |
| Analist kapsamı | Low |
| Son güncelleme | 01 May 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Anlatı Güncellemesi • May 21
STX: Pediatric And Asia Regulatory Milestones Will Drive Future Earnings Upside
Shield Therapeutics’ latest analyst price target has been set at £0.14, with analysts attributing this unchanged fair value to a slightly adjusted discount rate, modestly revised revenue growth and profit margin assumptions, and a recalibrated future P/E multiple. What's in the News MEDLEAP Pharma, a subsidiary of Vital KSK Holdings Inc., enrolled the first patient in a Phase II exploratory clinical trial in Japan evaluating ACCRUFeR (ferric maltol) for Pulmonary Arterial Hypertension.Anlatı Güncellemesi • May 04
STX: Pediatric And Asia Expansion Will Drive Future Earnings Upside
Analysts have adjusted their price target on Shield Therapeutics to £0.14 per share, with the change linked to updated assumptions that maintain the fair value level while recalibrating revenue growth, profit margin and future P/E expectations. What's in the News Partner MEDLEAP Pharma enrolled the first patient in a Phase II clinical trial in Japan testing ACCRUFeR (ferric maltol) as a potential treatment for pulmonary arterial hypertension, following prior confirmation of the development plan by Japan's Pharmaceuticals and Medical Devices Agency (Product-Related Announcement).Anlatı Güncellemesi • Apr 18
STX: Expanded Pediatric Reach And China Entry Will Support Stronger Future Earnings
Analysts have trimmed their fair value estimate for Shield Therapeutics to £0.14 per share, citing updated assumptions that combine a lower revenue growth outlook with a higher projected profit margin and a reduced future P/E multiple. What's in the News EMA's Committee for Medicinal Products for Human Use issued a positive opinion to extend FeRACCRU's indication to include adolescents, so it is now indicated for iron deficiency in adults and pediatric patients 12 years and older in Europe, with all measures in the agreed Pediatric Investigation Plan confirmed as fulfilled (Key Developments).Analiz Makalesi • Apr 12
Shield Therapeutics plc (LON:STX) Released Earnings Last Week And Analysts Lifted Their Price Target To UK£0.17
It's been a good week for Shield Therapeutics plc ( LON:STX ) shareholders, because the company has just released its...Anlatı Güncellemesi • Apr 03
STX: Pediatric And China Approvals Will Expand Future Earnings Power
Analysts have maintained their fair value estimate for Shield Therapeutics at £0.14. The discount rate remains unchanged, and updated assumptions for revenue growth, profit margin and future P/E support the latest price target view.
Anlatı Güncellemesi • Mar 20
STX: Pediatric Label Expansion And Added Exclusivity Will Support Future Upside
Analysts have kept their fair value framework for Shield Therapeutics broadly unchanged, with a slightly adjusted profit margin outlook and future P/E assumption. These updates feed into a refreshed price target in £ terms that remains closely aligned with the prior figure.Anlatı Güncellemesi • Mar 06
STX: Pediatric Expansion And China Filing Will Redefine Earnings Power
Analysts have lifted their price target for Shield Therapeutics to £0.14 from £0.10, citing updated assumptions for fair value, discount rate, revenue, profit margin and future P/E that they view as better aligned with the company’s current outlook. What's in the News Shield Therapeutics filed and received acceptance of a Marketing Authorisation Application for ACCRUFeR with China’s National Medical Products Administration for adults with iron deficiency, supported by prior US FDA data and a Phase 3 study in Chinese adults with iron deficiency anemia and inflammatory bowel disease who are intolerant to oral ferrous products (Key Developments).Anlatı Güncellemesi • Feb 19
STX: Pediatric Expansion And Extended Exclusivity Will Support Future Upside Potential
Analysts have kept their fair value estimate for Shield Therapeutics broadly steady at £0.17 per share, reflecting only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that they see as refinements rather than a change in thesis. What's in the News The FDA approved an extension of the indication for ACCRUFeR (ferric maltol) to treat iron deficiency in adult and pediatric patients 10 years and older, following a priority review supported by a Phase 3 pediatric trial in children from 1 month of age with iron deficiency anemia (Key Developments).Anlatı Güncellemesi • Feb 05
STX: Expanded Pediatric Indications And New Market Approvals Will Drive Upside
Analysts have nudged their price target for Shield Therapeutics slightly higher, reflecting small adjustments to revenue growth, profit margin expectations, and the implied future P/E multiple. What's in the News Shield Therapeutics issued earnings guidance for 2026, indicating that it expects to deliver an operating profit in that year (company guidance).Anlatı Güncellemesi • Jan 22
STX: Pediatric Expansion And New Market Approvals Will Support Future Upside
Analysts have lifted their price target on Shield Therapeutics from £0.16 to about £0.17, citing updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. What’s in the News US FDA grants priority review approval to extend ACCRUFeR’s indication to adolescents, covering iron deficiency treatment in patients 10 years and older, backed by positive Phase 3 pediatric trial data (FORTIS/ST10-01-305) (Key Developments).Anlatı Güncellemesi • Jan 07
STX: Expanded Pediatric And Global Approvals Will Support Future Upside
Analysts have trimmed their price target on Shield Therapeutics slightly, citing updated expectations for revenue growth of about 41.81%, a lower projected profit margin of around 13.33% and a higher future P/E of roughly 17.49x. Together, these factors imply less upside potential from current levels in cash terms than previously estimated.Anlatı Güncellemesi • Dec 18
STX: Future US Label Expansion Could Still Leave Shares Vulnerable
Analysts have raised their price target for Shield Therapeutics from 0.03 dollars to 0.10 dollars, citing slightly stronger long term revenue growth expectations, while applying a higher discount rate and more conservative profit margin and valuation multiples. What's in the News Presentation of pediatric FORTIS PK sub study at the American Society of Hematology conference in December 2025 showed ferric maltol is well absorbed across pediatric age groups, with maltol rapidly metabolized and excreted, supporting its suitability for iron replacement in children and adolescents (company announcement).Anlatı Güncellemesi • Dec 04
STX: New Regulatory Approvals And Pediatric Data Will Drive Future Upside
Analysts have modestly increased their price target on Shield Therapeutics, citing slightly stronger projected revenue growth, a marginally lower profit margin, and a modestly higher future price-to-earnings multiple. What's in the News The Korean Ministry of Food and Drug Safety granted regulatory approval for ACCRUFeR (ferric maltol) in adults with iron deficiency, opening a new commercial market and triggering eligibility for milestones and royalties (company announcement).Analiz Makalesi • Nov 25
Shield Therapeutics plc's (LON:STX) Subdued P/S Might Signal An Opportunity
With a median price-to-sales (or "P/S") ratio of close to 2.6x in the Pharmaceuticals industry in the United Kingdom...Anlatı Güncellemesi • Nov 20
STX: FDA Priority Review and Regulatory Approvals Will Drive Significant Upside
Analysts have modestly raised their price target for Shield Therapeutics from $0.16 to $0.16 per share. This change reflects updated assumptions around discount rates and profit margins, while maintaining a cautiously optimistic outlook.Anlatı Güncellemesi • Nov 06
STX: Upcoming FDA Decision Will Drive Confidence After Positive Pediatric Results
Analysts have maintained their price target for Shield Therapeutics at $0.16, citing stable projections in key financial metrics, including revenue growth and profit margin improvements, as justification for the unchanged valuation. What's in the News Positive efficacy, tolerability, and palatability results for the ferric maltol pediatric FORTIS clinical trial were presented at the American Association of Pediatrics National Conference.Anlatı Güncellemesi • Oct 22
Analysts Maintain Target for Shield Therapeutics Amid Positive Clinical News and Stable Valuation Metrics
Narrative Update on Shield Therapeutics: Analyst Price Target Revision Analysts have maintained their price target for Shield Therapeutics at £0.16. This reflects confidence in the company's prospects, given stable fair value estimates and consistent growth expectations.Anlatı Güncellemesi • Oct 08
Global Aging Trends And Early Detection Will Unlock Markets
Analysts have raised their price target on Shield Therapeutics from $0.14 to $0.16 per share, citing improved profit margin expectations and a steady long-term outlook, despite minor adjustments to growth forecasts. What's in the News Positive efficacy, tolerability, and palatability results for ferric maltol pediatric FORTIS clinical trial were presented at the AAP National Conference, showing significant hemoglobin improvements with no serious adverse events reported (Key Developments).Analiz Makalesi • Aug 23
The Market Lifts Shield Therapeutics plc (LON:STX) Shares 76% But It Can Do More
Despite an already strong run, Shield Therapeutics plc ( LON:STX ) shares have been powering on, with a gain of 76% in...Yeni Anlatı • Aug 03
Global Aging Trends And Early Detection Will Unlock Markets
An expanding addressable market and greater screening activity are driving strong prescription growth and recurring revenues for Shield's main product.Analiz Makalesi • Jun 28
Shield Therapeutics plc (LON:STX) Soars 27% But It's A Story Of Risk Vs Reward
Shield Therapeutics plc ( LON:STX ) shares have had a really impressive month, gaining 27% after a shaky period...Analiz Makalesi • Feb 06
Even With A 26% Surge, Cautious Investors Are Not Rewarding Shield Therapeutics plc's (LON:STX) Performance Completely
Shield Therapeutics plc ( LON:STX ) shareholders have had their patience rewarded with a 26% share price jump in the...Analiz Makalesi • Oct 30
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Shield Therapeutics plc ( LON:STX ) share price has softened a substantial 28% over the previous 30 days, handing...Analiz Makalesi • Oct 12
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Aug 01
Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Despite an already strong run, Shield Therapeutics plc ( LON:STX ) shares have been powering on, with a gain of 44% in...Analiz Makalesi • Jun 13
Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Key Insights Shield Therapeutics will host its Annual General Meeting on 20th of June CEO Greg Madison's total...Analiz Makalesi • May 22
Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
Shield Therapeutics plc ( LON:STX ) shareholders are no doubt pleased to see that the share price has bounced 35% in...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 129 | 8 | 14 | 16 | 3 |
| 12/31/2027 | 104 | 11 | 9 | 11 | 3 |
| 12/31/2026 | 76 | 0 | 3 | 4 | 3 |
| 12/31/2025 | 50 | -18 | -4 | -3 | N/A |
| 9/30/2025 | 46 | -19 | -1 | 1 | N/A |
| 6/30/2025 | 41 | -21 | 2 | 5 | N/A |
| 3/31/2025 | 37 | -24 | -3 | -1 | N/A |
| 12/31/2024 | 32 | -27 | -9 | -7 | N/A |
| 9/30/2024 | 27 | -32 | -16 | -14 | N/A |
| 6/30/2024 | 21 | -36 | -23 | -21 | N/A |
| 3/31/2024 | 17 | -35 | -32 | -29 | N/A |
| 12/31/2023 | 13 | -33 | -40 | -37 | N/A |
| 9/30/2023 | 10 | -40 | -35 | -33 | N/A |
| 6/30/2023 | 7 | -47 | -30 | -28 | N/A |
| 3/31/2023 | 6 | -49 | -28 | -25 | N/A |
| 12/31/2022 | 5 | -50 | -25 | -23 | N/A |
| 9/30/2022 | 5 | -39 | -27 | -24 | N/A |
| 6/30/2022 | 4 | -30 | -31 | -27 | N/A |
| 3/31/2022 | 3 | -29 | -29 | -26 | N/A |
| 12/31/2021 | 2 | -27 | -27 | -25 | N/A |
| 9/30/2021 | 2 | -22 | -21 | -20 | N/A |
| 6/30/2021 | 3 | -18 | -16 | -16 | N/A |
| 3/31/2021 | 9 | -11 | -9 | -9 | N/A |
| 12/31/2020 | 14 | -4 | -2 | -2 | N/A |
| 9/30/2020 | 13 | -3 | -1 | -1 | N/A |
| 6/30/2020 | 11 | -2 | 0 | 0 | N/A |
| 3/31/2020 | 6 | -6 | -4 | -3 | N/A |
| 12/31/2019 | 1 | -12 | -7 | -5 | N/A |
| 9/30/2019 | 8 | -4 | N/A | 1 | N/A |
| 6/30/2019 | 15 | 3 | N/A | 6 | N/A |
| 3/31/2019 | 15 | 0 | N/A | 3 | N/A |
| 12/31/2018 | 15 | -2 | N/A | 0 | N/A |
| 9/30/2018 | 8 | -13 | N/A | -9 | N/A |
| 6/30/2018 | 1 | -24 | N/A | -19 | N/A |
| 3/31/2018 | 1 | -26 | N/A | -21 | N/A |
| 12/31/2017 | 1 | -26 | N/A | -22 | N/A |
| 9/30/2017 | 1 | -24 | N/A | -21 | N/A |
| 6/30/2017 | 0 | -21 | N/A | -19 | N/A |
| 3/31/2017 | 0 | -19 | N/A | -16 | N/A |
| 12/31/2016 | 0 | -19 | N/A | -13 | N/A |
| 9/30/2016 | 0 | -12 | N/A | -12 | N/A |
| 6/30/2016 | 0 | -4 | N/A | -10 | N/A |
| 3/31/2016 | 0 | -19 | N/A | -8 | N/A |
| 12/31/2015 | N/A | -35 | N/A | -6 | N/A |
| 9/30/2015 | 0 | -41 | N/A | -5 | N/A |
| 6/30/2015 | 0 | -49 | N/A | -4 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: STX önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.4% ) daha hızlı bir büyüme olarak değerlendiriliyor.
Kazançlar ve Piyasa: STX önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.
Yüksek Büyüme Kazançları: STX önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.
Gelir ve Pazar: STX şirketinin gelirinin (yıllık 24.1% ) UK pazarından (yıllık 4.5% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: STX şirketinin gelirinin (yıllık 24.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: STX 3 yıl içinde kârsız olması bekleniyor.
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/26 11:00 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Shield Therapeutics plc 10 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Howard Miller | Canaccord Genuity |
| Mark Brewer | Cavendish |
| Michael Mitchell | Cavendish |